Overview
This is a post-marketing observational study aimed to evaluated the safety profile of Effivia®, a biosimilar of bevacizumab, in mexican patients with different types of cancer.
Eligibility
Inclusion Criteria:
- Male and female patients, 18 years and older.
- Patients with metastatic colorectal cancer,unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, metastatic renal cell carcinoma, persistent, recurrent, or metastatic cervical cancer, or epithelial ovarian, fallopian tube, or primary peritoneal cancer naive to bevacizumab therapy (Effivia®).
- Provide written informed consent.
Exclusion Criteria:
- History of recent surgery or wound healing complications.
- History of gastrointestinal perforations or fistula.
- History of renal injury and proteinuria.
- Recent surgical intervention.
- Pregnant or nursing women.
- History of bevacizumab, monoclonal antibodies, or CHO cells-derived products hypersensitivity.
- Other safety concerns or bevacizumab contraindications.